Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development
Search Refinements
Search Results: Drug Discovery & Development
1-15 of 4925 results
Zogenix begins dosing in Phase Ib Relday multi-dose clinical trial to treat schizophrenia
By PBR Staff Writer
US-based pharmaceutical firm Zogenix has started dosing patients in its multi-dose Phase Ib clinical trial of Relday, a proprietary, long-acting, subcutaneously injected formulation of risperidone being investigated to treat schizophrenia.
Drug Research > Drug Discovery & Development > News
Mast Therapeutics to develop vepoloxamer to treat chronic heart failure
By PBR Staff Writer
US-based biopharmaceutical firm Mast Therapeutics is planning to develop vepoloxamer (MST-188) to treat patients with chronic heart failure.
Drug Research > Drug Discovery & Development > News
Lilly partners with China's Innovent for new oncology therapies
By PBR Staff Writer
Eli Lilly and Company and China-based biopharmaceutical firm Innovent Biologics have collaborated to create possible new treatment options for cancer patients in China and around the world.
Drug Research > Drug Discovery & Development > News
AbbVie enters into license deal with C2N Diagnostics for Alzheimer's disease therapy
By PBR Staff Writer
US-based AbbVie and C2N Diagnostics, a protein diagnostic and therapeutic discovery firm, have collaborated for the development and commercialization of a portfolio of anti-tau antibodies to treat Alzheimer's disease (AD) and other neurological disorders.
Drug Research > Drug Discovery & Development > News
Lilly, Hanmi to develop BTK inhibitor to treat autoimmune diseases
By PBR Staff Writer
Eli Lilly and Company has entered into an exclusive license and collaboration agreement with Hanmi Pharmaceutical to develop and commercialize the latter's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, to treat autoimmune and other diseases.
Drug Research > Drug Discovery & Development > News
Stability Issues Related to Soft Gelatin Capsule Development
Stability issues are a challenge and never ending concern for formulators. The reactivity of formulations depends on many factors but it is generally recognized that labile drugs in aqueous forms are sometimes the worst cases and in this regard, this should be a true statement for the development teams which work with SGC´s.
Drug Research > Drug Discovery & Development > Press Releases
Amgen reports positive results from OSLER-1 and OSLER-2 trials of Repatha
By PBR Staff Writer
Amgen has reported positive one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase II (OSLER-1) and Phase III (OSLER-2) open-label extension trials of Repatha (evolocumab).
Drug Research > Drug Discovery & Development > News
Sanofi and Regeneron report 18-month results of ODYSSEY long term trial of Praluent
By PBR Staff Writer
Sanofi and Regeneron Pharmaceuticals have reported positive 18-month results of a Phase III ODYSSEY long term trial of Praluent (alirocumab), an investigational therapy, in patients with hypercholesterolemia.
Drug Research > Drug Discovery & Development > News
Evotec, Second Genome to discover new treatment for microbiome-mediated diseases
By PBR Staff Writer
German drug discovery firm Evotec and US-based biotechnology company Second Genome have entered into a partnership for small molecule-based discovery and development activities to treat microbiome-mediated diseases.
Drug Research > Drug Discovery & Development > News
EMD Serono amends deal with Opexa for multiple sclerosis drug Tcelna
By PBR Staff Writer
Merck subsidiary EMD Serono has made changes to its agreement with Opexa Therapeutics to develop and commercialize its investigational compound Tcelna (imilecleucel-T) for the treatment of multiple sclerosis.
Drug Research > Drug Discovery & Development > News
Korean biotech firm G-treeBNT obtains funding to develop RGN-259/GBT-201 in US
By PBR Staff Writer
RegeneRx Biopharmaceuticals' joint venture partner and licensee G-treeBNT is set to receive $7.28m from the Korean Government and Venture Fund to expand development of its product candidate, RGN-259 (GBT-201), in the US.
Drug Research > Drug Discovery & Development > News
Sandoz receives FDA approval for Zarxio
Generic pharmaceutical company Sandoz’s Zarxio has received an US Food and Drug Administration (FDA) approval for all indications included in the reference product's label.
Drug Research > Drug Discovery & Development > News
UK’s NICE draft guidance recommends apixaban for blood clots
By PBR Staff Writer
The National Institute for Health and Care Excellence (NICE) in the UK has published a new draft guidance which recommends apixaban (Eliquis) as an option for treating and preventing potentially fatal blood clots.
Drug Research > Drug Discovery & Development > News
Biovian at BIO-Europe Spring March 9-11, 2015
Biovian's CEO, Dr. Knut Ringbom will be available for in-depth discussions with your delegates at the partnering offered at the conference.
Drug Research > Drug Discovery & Development > Press Releases

PBR Supplier Recommendations

Vetter Pharma International - High-Quality Aseptically Pre-Filled Injection Systems
From preclinical development through commercial supply.... Drug Research > Drug Discovery & Development > Suppliers
ERT - Getting it done. Right.
ERT is a leading global provider of high-quality patient safety and efficacy endpoint data collection solutions for use by biopharmaceutical companies during clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle.... Drug Research > Drug Discovery & Development > Suppliers
Biovian - cGMP Contract Manufacturing of Biopharmaceuticals
Biovian is a dynamic and effective new generation one-stop-shop CMO in cGMP contract manufacturing of biopharmaceuticals. Biovian's services cover the full range from antigen isolation, expression, vector construction, cell line cultivation, cGMP protein purification to product fill and finish.... Drug Research > Drug Discovery & Development > Suppliers
Tosoh Bioscience - Your Specialist in Separation
Tosoh Bioscience is an acknowledged global leader in the field of liquid chromatography with a strong focus on bioseparations. We offer solutions for research, drug discovery, clinical chemistry, environmental analysis, manufacturing and other industrial applications. ... Drug Research > Drug Discovery & Development > Suppliers
Medical Research Network - Clinical Trial Support Organisation
The Medical Research Network (MRN) is a unique clinical trial support organisation (CTSO). The MRN has been involved in the conduct of over 50 clinical trials across a wide range of therapeutic areas, in particular oncology and rheumatology.... Drug Research > Drug Discovery & Development > Suppliers
See more

PBR White Paper Recommendations

Best Practices for Streamlining Electronic Implementation of Established COAs; Copyright January 2015 By ERT
This paper addresses the best practices for building an electronic Clinical Outcome Assessment (eCOA) solution in support of clinical research as it relates to the operational and licensing compliance aspects of administering COAs on electronic platforms.... Drug Research > Drug Discovery & Development > White Papers Symptoms and Impact of COPD Assessed by an Electronic Diary in Patients with Moderate-to-Severe COPD: Psychometric Results from the SHINE Study; International Journal of COPD; January 2015. By ERT
This paper presents the results of psychometric assessment data from a COPD eDiary developed by Novartis to provide a more detailed assessment of symptom frequency and severity and their impact on patients with COPD.... Drug Research > Drug Discovery & Development > White Papers The Use of Ambulatory Blood Pressure Monitoring in Drug Development; Copyright, January 2015 By ERT
This white paper delves into the basics of blood pressure, along with the well-documented limitations of standard and digital office blood pressure measurements. It reviews ABPM device functionality, common drug classes where blood pressure monitoring comes into play and compares the advantages and disadvantages of different monitoring options in clinical studies.... Drug Research > Drug Discovery & Development > White Papers The Use of Continuous ECG Recordings (Holters) in Drug Development; Copyright, December 2014 By ERT
Continuous 12 lead ECG recorders, often referred to as Holter devices, offer specific advantages to be considered over the standard 12 lead ECGs often collected during clinical trials for cardiac safety. This white paper explores the history of Holters, how sponsors, sites, and patients use these devices, and the benefits of continuous ECG recordings.... Drug Research > Drug Discovery & Development > White Papers Predictive Value of Baseline electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) Assessments for Identifying Risk of Prospective Reports of Suicidal Behavior During Clinical Research; Innovations in Clinical Neuroscience; November 2014 By ERT
This meta-analysis examined the ability of baseline eC-SSRS lifetime suicidal ideation and behavior categories to predict prospective reports of suicidal behavior in psychiatric and non-psychiatric research participants. The review of over 74,000 eC-SSRS assessments determined that increasingly more severe lifetime suicidal ideation at baseline was associated with a progressively greater likelihood of prospectively reported suicidal behavior during study participation.... Drug Research > Drug Discovery & Development > White Papers See more
1-15 of 4925 results